Keep up to date with our latest partnering deals and highlights

Below is a selection of news releases describing recent deals completed by AstraZeneca and our biologics arm, MedImmune.

Monday, 22 April 2013
Horizon Discovery Announces Oncology Drug Discovery Collaboration with AstraZeneca Cambridge, UK, 22 April 2013: Horizon Discovery (Horizon) and AstraZeneca have entered into an exclusive collaboration and license agreement to explore Horizon’s first-in-class kinase target programme, HD-001, as a means of developing novel therapies for multiple cancer types.
Monday, 22 April 2013
AstraZeneca and BIND Therapeutics announce worldwide development and commercialisation agreement for cancer nanomedicine AstraZeneca and BIND Therapeutics announced today that they have entered into a strategic collaboration to develop and commercialise an Accurin™, a targeted and programmable cancer nanomedicine from BIND’s Medicinal Nanoengineering platform, based on a molecularly targeted kinase inhibitor developed and owned by AstraZeneca.
Wednesday, 3 April 2013
MedImmune, AstraZeneca’s biologics arm, acquires AlphaCore Pharma AstraZeneca today announced that MedImmune, its global biologics research and development arm, has acquired AlphaCore Pharma, an Ann Arbor, Michigan-based biotechnology company focused on the development of ACP-501, a recombinant human lecithin-cholesterol acyltransferase (LCAT) enzyme.
Download our brochure

Download your comprehensive guide to partnering with us.

Meet us at an event

Calendar iconView our full event calendar to see events we are attending.

View calendar